Antibody-modified lipid nanoparticles for selective delivery of siRNA to tumors expressing membrane-anchored form of HB-EGF

Biochemical and Biophysical Research Communications

Volumn 449, Issue 4, 2014, Pages 460-465

  Okamoto, Ayaka ^a   Asai, Tomohiro ^a   Kato, Hiroki ^a   Ando, Hidenori ^a   Minamino, Tetsuo ^b   Mekada, Eisuke ^c   Oku, Naoto ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Antibody; Breast cancer; HB EGF; Lipid nanoparticles; SiRNA delivery

Indexed keywords

HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MESSENGER RNA; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG FORMULATION; GENE EXPRESSION; GENE SILENCING; MEMBRANE BINDING; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANTIBODY; BREAST CANCER; HB-EGF; LIPID NANOPARTICLES; SIRNA DELIVERY;

ANIMALS; BREAST NEOPLASMS; CERCOPITHECUS AETHIOPS; FEMALE; GENE SILENCING; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NANOPARTICLES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; VERO CELLS;

EID: 84902852959     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.05.043     Document Type: Article

References (27)

1. H.M. Aliabadi, R. Maranchuk, C. Kucharski, P. Mahdipoor, J. Hugh, H. Uludag, Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy, J. Control Release 172 (2013) 219-228
2. Y. Wang, Z. Xu, S. Guo, et al., Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis, Mol. Ther. 21 (2013) 1919-1929
3. S.T. Chan, N.C. Yang, C.S. Huang, J.W. Liao, S.L. Yeh, Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivo, PLoS One 8 (2013) e54255
4. Y. Sakurai, H. Hatakeyama, Y. Sato, et al., RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system, J. Control Release 173C (2013) 110-118
5. P. Liu, H. Yu, Y. Sun, M. Zhu, Y. Duan, A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery, Biomaterials 33 (2012) 4403-4412
6. H. Lee, A.K. Lytton-Jean, Y. Chen, et al., Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery, Nat. Nanotechnol. 7 (2012) 389-393
7. T. Asai, S. Matsushita, E. Kenjo, et al., Dicetyl phosphatetetraethylenepentamine- based liposomes for systemic siRNA delivery, Bioconjug. Chem. 22 (2011) 429-435
8. H. Ando, A. Okamoto, M. Yokota, et al., Development of a miR-92a delivery system for anti-angiogenesis-based cancer therapy, J. Gene Med. 15 (2013) 20- 27
9. H. Ando, A. Okamoto, M. Yokota, T. Asai, T. Dewa, N. Oku, Polycation liposomes as a vector for potential intracellular delivery of microRNA, J. Gene Med. 15 (2013) 375-383
10. H. Koide, T. Asai, K. Furuya, et al., Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector, Biol. Pharm. Bull. (2011) 602-608
11. E. Kenjo, T. Asai, N. Yonenaga, et al., Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy, Biol. Pharm. Bull. 36 (2013) 287-291
12. N. Yonenaga, E. Kenjo, T. Asai, et al., RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment, J. Control Release 160 (2012) 177-181
13. T. Asai, T. Tsuzuku, S. Takahashi, et al., Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery, Biochem. Biophys. Res. Commun. 444 (2014) 599-604
14. J.C. Brenner, B. Ateeq, Y. Li, et al., Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer, Cancer Cell 19 (2011) 664-678
15. A. Mishra, S. Liu, G.H. Sams, et al., Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation, Cancer Cell 22 (2012) 645-655
16. S. Miyamoto, H. Yagi, F. Yotsumoto, T. Kawarabayashi, E. Mekada, Heparinbinding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy, Cancer Sci. 97 (2006) 341-347
17. P.P. Ongusaha, J.C. Kwak, A.J. Zwible, et al., HB-EGF is a potent inducer of tumor growth and angiogenesis, Cancer Res. 64 (2004) 5283-5290 (Pubitemid 39006548)
18. K. Nishikawa, T. Asai, H. Shigematsu, et al., Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer, J. Control Release 160 (2012) 274-280
19. M. Hamaoka, I. Chinen, T. Murata, S. Takashima, R. Iwamoto, E. Mekada, Antihuman HB-EGF monoclonal antibodies inhibiting ectodomain shedding of HBEGF and diphtheria toxin binding, J. Biochem. 148 (2010) 55-69
20. T. Ishida, D.L. Iden, T.M. Allen, A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs, FEBS Lett. 460 (1999) 129-133 (Pubitemid 29479257)
21. K. Goishi, S. Higashiyama, M. Klagsbrun, et al., Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity, Mol. Biol. Cell 6 (1995) 967-980
22. P. Estep, F. Reid, C. Nauman, et al., High throughput solution-based measurement of antibody-antigen affinity and epitope binding, mAbs 5 (2013) 270-278
23. S. Bhattacharyya, R. Bhattacharya, S. Curley, M.A. McNiven, P. Mukherjee, Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis, Proc. Natl. Acad. Sci. U.S.A. 107 (2010) 14541- 14546
24. S. Dou, Y.D. Yao, X.Z. Yang, et al., Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy, J. Control Release 161 (2012) 875-883
25. A. Kimura, M. Terao, A. Kato, et al., Upregulation of Nacetylglucosaminyltransferase- V by heparin-binding EGF-like growth factor induces keratinocyte proliferation and epidermal hyperplasia, Exp. Dermatol. 21 (2012) 515-519
26. M. Hieda, M. Koizumi, C. Higashi, T. Tachibana, T. Taguchi, S. Higashiyama, The cytoplasmic tail of heparin-binding EGF-like growth factor regulates bidirectional intracellular trafficking between the plasma membrane and ER, FEBS Open Bio 2 (2012) 339-344
27. K. Maruyama, N. Takahashi, T. Tagawa, K. Nagaike, M. Iwatsuru, Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo, FEBS Lett. 413 (1997) 177-180. (Pubitemid 27348659)